Ovreena®
- Contains 30 mcg ethinylestradiol and 150 mcg levonorgestrel, exactly the same active ingredients as Ovranette® 1,2
- Indicated for the prevention of pregnancy in women who elect to use oral contraception
- Side effects may include mood changes and depression.
- Causes changes in the endometrium and cervical mucus1,2
- Reliable, highly effective and well tolerated oral contraceptive when taken correctly1
- OVREENA® has a Pearl Index of 0.44
- OVREENA® is GMS Reimbursed
OVREENA® is suitable for use in the following patient groups:5,6
- Women on the GMS reimbursement scheme
- Women who want autonomy and control over their menstrual cycle
- Women aged up to 50 years with no other medical conditions
- Women ≥6 months postpartum if fully breast feeding
- Women ≥6 weeks postpartum if not breast feeding
- Women with dysmenorrhoea who have an irregular, heavy or prolonged bleeding pattern
- Women with endometriosis
References:
1. Ovreena® SPC
2. Ovranette® SPC
available at www.medicines.ie
3. MIMS Ireland (August 2017) ‘Contraception’ MPI Media Ltd, Dublin.
4. Faculty of Sexual and Reproductive Health Care (FSRH). First Prescription of Combined Oral Contraception. Clinical Effectiveness Unit July 2006 (Updated January 2007) London: FSRH, 2007.
5. Faculty of Sexual and Reproductive Health Care (FSRH). UK Medical Eligibility Criteria for Contraceptive Use. UKMEC 2016. London: FSRH, 2016.
6. WHO Guidelines. Medical Eligibility Criteria for contraceptive use 2015 update
If you have a medical query about a Consilient Health medicine, please contact Consilient Health at drugsafety@consilienthealth.com or +353 (0)1 2057766.
For all other queries, please contact our Irish office at Tel: +353 (0)1 2057760, Fax: +353 (0)1 2698919 or irishoffice@consilienthealth.com
Copyright ©2015 Consilient Health Ltd. All rights reserved. The information on this website is intended for healthcare professionals registered in the Republic of Ireland only.
IE/OCS/0817/0058e Date of preparation: April 2019
